Literature DB >> 32561866

ICI rechallenge in mRCC.

David Killock1.   

Abstract

Mesh:

Year:  2020        PMID: 32561866     DOI: 10.1038/s41571-020-0407-x

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.

Authors:  Anita Gul; Tyler F Stewart; Charlene M Mantia; Neil J Shah; Emily Stern Gatof; Ying Long; Kimberly D Allman; Moshe C Ornstein; Hans J Hammers; David F McDermott; Michael B Atkins; Michael Hurwitz; Brian I Rini
Journal:  J Clin Oncol       Date:  2020-06-03       Impact factor: 44.544

2.  Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.

Authors:  Praful Ravi; Charlene Mantia; Christopher Su; Karl Sorenson; Dean Elhag; Nityam Rathi; Ziad Bakouny; Neeraj Agarwal; Yousef Zakharia; Brian A Costello; Rana R McKay; Vivek Narayan; Ajjai Alva; Bradley A McGregor; Xin Gao; David F McDermott; Toni K Choueiri
Journal:  JAMA Oncol       Date:  2020-10-01       Impact factor: 31.777

  2 in total
  1 in total

1.  Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade.

Authors:  T Anders Olsen; Dylan J Martini; Subir Goyal; Yuan Liu; Sean T Evans; Benjamin Magod; Jacqueline T Brown; Lauren Yantorni; Greta Anne Russler; Sarah Caulfield; Jamie M Goldman; Wayne B Harris; Omer Kucuk; Bradley C Carthon; Viraj A Master; Bassel Nazha; Mehmet Asim Bilen
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.